Cloughesy Cloughesy TF TF Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma Nat Med Nat Med 2019 2019 25 25 3 3 477 477 486 486 10.1038/s41591-018-0337-7 10.1038/s41591-018-0337-7 supplied-pmid 30742122? The gene discussed is PDCD1; the disease is glioblastoma.